Mylan Signs Licensing Agreement With 3M Pharmaceuticals.Business Editors PITTSBURGH--(BUSINESS WIRE)--June 7, 2002 Mylan Laboratories Inc. (NYSE NYSE See: New York Stock Exchange : MYL MYL Mind Your Language MYL Made You Laugh MYL Miss You Lots MYL Meet You Later MYL Miss You Loads ) announced today that it has reached an agreement with 3M Pharmaceuticals for an exclusive supply and distribution agreement to sell Flecainide Acetate fle·cai·nide acetate n. A drug that stabilizes membranes and has local anesthetic activity, used in the treatment of ventricular arrhythmias. flecainide acetate, n brand name: Tambocor; drug class: Tablets in bottles of 100 of the 50 mg, 100 mg and 150 mg strengths. In addition, UDL UDL Universal Design for Learning UDL Universitat de Lleida (Spain) UDL Universal Data Link UDL Urban Debate League UDL Uniformly Distributed Load (mechanics, building trade) UDL User Defined Logic Laboratories, Inc., a Mylan subsidiary, will be shipping Flecainide Acetate to the institutional marketplace in unit dose strips (10 X 10's) for the 50 mg and 100 mg strengths. Mylan Flecainide Acetate is therapeutically equivalent to 3M Pharmaceuticals Tambocor(R) Tablets. Tambocor is a $110 million brand and is indicated as an antiarrhythmic antiarrhythmic /an·ti·ar·rhyth·mic/ (-ah-rith´mik) 1. preventing or alleviating cardiac arrhythmias. 2. an agent that so acts. an·ti·ar·rhyth·mic adj. . The launch of Mylan labeled Flecainide Acetate is another important addition to our growing line and strengthens Mylan's position as a leader in the generic drug generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. industry. Mylan Laboratories Inc., is a leading pharmaceutical company that develops, manufacturers and markets generic and proprietary prescription pharmaceutical products. The company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit www.mylan.com To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking statements regarding our anticipated financial results and estimates, business prospects and products in research and under going development, all of which involve substantial risks and uncertainties. Such risks and uncertainties are not predictable or quantifiable; consequently, should known or unknown risks or uncertainties materialize, or should our assumptions or estimates prove inaccurate, actual results could differ materially from those expressed or implied by such forward-looking statement. For further details and a discussion of such risks and uncertainties, we encourage you to read Forward-looking Statements found in our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended March 31, 2001, and in our periodic reports on Forms 10-Q and 8-K (if any). We assume no obligation to update any forward-looking statements presented here today, whether as a result of new information, future events or otherwise. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion